NaQuinate (Osteopura)
Osteoporosis and Osteopenia
Phase 1Active
Key Facts
About Haoma Medica
Haoma Medica is a private, clinical-stage biotech developing NaQuinate (Osteopura), a novel oral therapeutic for osteoporosis and osteopenia. The compound is a naturally occurring vitamin K catabolite that uniquely regulates both bone-building osteoblasts and bone-resorbing osteoclasts, aiming to improve bone quality and quantity with a favorable safety profile. The company has completed a Phase I safety study and holds an international patent portfolio, positioning it to address a large market with significant unmet need due to poor adherence to current therapies. Its strategy includes advancing clinical proof-of-concept studies while commercializing early-stage nutraceutical products.
View full company profile